Programme SOM3355 to Treat Chorea in Huntington Sisease and Tardive Dyskinesia

10th February 2020

SOM3355 successfully finished Clinical Phase 2a PoC. SOM3355 is the only safe VMAT2(-) not related to serious adverse events like depression, suicide, parkinsonism or neuroleptic syndrome.

It has a potential sales peak of €1,8B. Regulatory roadmap is made by Camargo, US.

Huntington’s disease is an inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. Huntington’s disease has a broad impact on a person’s functional abilities and usually results in movement, thinking (cognitive) and psychiatric disorders.

More About This Company